

Patient: [REDACTED]
 DOB: [REDACTED] Age: [REDACTED] Gender: [REDACTED]
 Patient Identifiers: [REDACTED] [REDACTED]
 Visit Number (FIN): [REDACTED]

Client: [REDACTED]
 Physician: [REDACTED]


ARUP Test Code: 0093399
 Collection Date: 11/28/2016
 Received in lab: 11/28/2016
 Completion Date: 12/01/2016

**Circulating Tumor Cell (CTC) Count Current Result: 30 H
 Metastatic Cancer Type: Prostate**

Metastatic Prostate Cancer: A CTC count of 5 or more per 7.5mL of blood at any time during the course of the disease is associated with a poor prognosis and is predictive of shorter progression free survival and overall survival.

These results have been reviewed and approved by [REDACTED], MD, PhD.

CTC Count - Longitudinal Results*



CTC Count

Result	Collection Date
30 H	11/28/2016
5 H	8/29/2016

*Cell count limits for the graph are 0 - 500. Up to the 20 most recent patient CTC results may be represented.

Test Information

Consecutive test results are displayed on this chart; however, this result set may be incomplete due to variations in the demographic information submitted for prior tests. If the information shown on this chart appears incomplete, please consult this patient's prior charts.

Circulating Tumor Cell Count - CellSearch

The CellSearch Circulating Tumor Cell kit, manufactured by Janssen Diagnostics and performed on their celltrack™ analyzer system, is intended for the quantification of circulating tumor cells (CTC) of epithelial origin in whole blood. This assay can be used to predict progression free and overall survival in patients with metastatic breast, colon and prostate cancer. For additional information and assay limitations refer to the Breast Cancer Management Assays, Prostate Cancer, or Colorectal Cancer topic at arupconsult.com.



Patient: [REDACTED]
 ARUP Accession: 16-333-103900
 0